Long-Term Safety Data for Novel Chronic Idiopathic Constipation Drug Announced

The study included a total of 2,370 patients and lasted for up to 72 weeks
The study included a total of 2,370 patients and lasted for up to 72 weeks

At the American College of Gastroenterology (ACG) annual scientific meeting, Synergy presented new long-term safety data of plecanatide for the treatment of chronic idiopathic constipation (CIC)

In the long-term study (n=2,370), CIC patients treated with plecanatide 3mg or 6mg daily for up to 72 weeks had low adverse events and low discontinuation rates. The most common adverse events were diarrhea (7.1%) and urinary tract infection (2.2%) for both plecanatide dose groups. Adverse events leading to discontinuation were seen in 5.3% of patients treated with plecanatide, with discontinuation due to diarrhea occurring in 3.1% of patients.   

Related Articles

Additional data from an integrated efficacy and safety analysis was also presented. The findings were consistent with those of two previously announced Phase 3 double-blind, placebo-controlled studies that evaluated >2,600 patients with CIC over a 12-week treatment period. Also, the findings confirmed a significantly greater response rate of durable overall complete spontaneous bowel movements (CSBM) in each of the plecanatide 3mg (20.5%) and 6mg (19.8%) dose groups vs. the placebo group (11.5%, P<0.001 for both doses).

Plecanatide, an investigational oral compound, is currently being evaluated for the treatment of CIC and irritable bowel syndrome with constipation (IBS-C). It is designed to replicate the activity of uroguanylin, a naturally occurring human gastrointestinal (GI) peptide. It works locally in the proximal small intestine to stimulate digestive fluid movement and help regular bowel function. 

For more information visit SynergyPharma.com.

Loading links....